MDXG MiMedx Group Inc.

MiMedx to Participate at the H.C. Wainwright BioConnect 2021 Conference

MiMedx to Participate at the H.C. Wainwright BioConnect 2021 Conference

MARIETTA, Ga., Jan. 04, 2021 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MiMedx” or the “Company”), an industry leader in advanced wound care and a therapeutic biologics company, today announced that Timothy R. Wright, Chief Executive Officer, and Dr. Robert Stein, Executive Vice President, Research & Development, will participate in a fireside chat at the H.C. Wainwright BioConnect 2021 Virtual Conference held January 11-14, 2021.

The pre-recorded fireside chat will be available on the Events page of the Investors section of the Company’s website at beginning on Monday, January 11, 2021 at 6:00 AM Eastern Time and will be accessible for approximately 90 days.

About MiMedx

MiMedx® is an industry leader in advanced wound care and a therapeutic biologics company developing and distributing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare. The Company processes the human placental tissue utilizing its proprietary PURION® process methodology, among other processes, to produce allografts by employing aseptic processing techniques in addition to terminal sterilization. MiMedx has supplied more than two million allografts, through both direct and consignment shipments. For additional information, please visit .

Contacts:

Investors

Jack Howarth

404-360-5681



EN
04/01/2021

Underlying

MDXGMiMedx Group Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on MiMedx Group Inc.

 PRESS RELEASE
Free
MDXG MiMedx Group I...

MIMEDX Comments on CY 2026 Medicare Physician Fee Schedule Final Rule

MIMEDX Comments on CY 2026 Medicare Physician Fee Schedule Final Rule Company is Well Positioned to Continue to Compete and Grow MARIETTA, Ga., Nov. 03, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today commented on the Centers for Medicare and Medicaid Services (“CMS”) release of the CY 2026 Physician Fee Schedule (“PFS”) final rule, which was published on Friday. “Over the last several years, we have actively engaged with numerous stakeholders to advocate for much-needed reform of the Medicare reimbursement system for skin substitutes. CMS i...

November 3, 2025 1 EN
 PRESS RELEASE
Free
MDXG MiMedx Group I...

MIMEDX Announces Record Revenue for Third Quarter 2025

MIMEDX Announces Record Revenue for Third Quarter 2025 Second Consecutive Quarter of Highest Quarterly Net Sales in MIMEDX History  Third Quarter Net Sales of $114 million Grew 35% Year-Over-Year Third Quarter GAAP Net Income and Diluted Earnings Per Share were $17 Million and $0.11, Respectively Third Quarter Adjusted EBITDA was $35 Million, or 31% of Net Sales Raises 2025 Net Sales Growth and Adjusted EBITDA Expectations Management to Host Conference Call Today, October 29, 2025, at 4:30 PM ET MARIETTA, Ga., Oct. 29, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MI...

October 29, 2025 1 EN
 PRESS RELEASE
Free
MDXG MiMedx Group I...

MIMEDX to Host Third Quarter 2025 Operating and Financial Results Conf...

MIMEDX to Host Third Quarter 2025 Operating and Financial Results Conference Call on October 29 MARIETTA, Ga., Oct. 15, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the third quarter ended September 30, 2025 after the market close on Wednesday, October 29, 2025. The MIMEDX senior management team will host a webcast and conference call to review its results beginning at 4:30 p.m. Eastern Time on the same day. The conference call can be accessed using the following informat...

October 15, 2025 1 EN
 PRESS RELEASE
Free
MDXG MiMedx Group I...

MIMEDX Announces Launch of EPIXPRESS®

MIMEDX Announces Launch of EPIXPRESS® Next-Generation, Lyophilized Human Placental Allograft Further Expands Company’s Broad Portfolio of Advanced Wound Care (“AWC”) Products MARIETTA, Ga., Oct. 06, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced the launch of EPIXPRESS®, the Company’s newest addition to its portfolio of AWC solutions. “I am pleased to announce our latest, organically developed addition to our product portfolio today with the launch of EPIXPRESS,” said Joseph H. Capper, MIMEDX Chief Executive Officer. “With EPIXPRE...

October 6, 2025 1 EN
 PRESS RELEASE
Free
MDXG MiMedx Group I...

MIMEDX to Sponsor and Attend Symposium on Advanced Wound Care (SAWC) F...

MIMEDX to Sponsor and Attend Symposium on Advanced Wound Care (SAWC) Fall To Present Six Posters Featuring the Company’s Latest Product Innovations MARIETTA, Ga., Sept. 03, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced its schedule for the Symposium on Advanced Wound Care (SAWC) Fall meeting taking place September 3-6 in Las Vegas, NV. SAWC remains a premier event for clinicians and industry professionals to explore the latest clinical evidence and innovations in advanced wound care. The Company will showcase its leading advanced ...

September 3, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch